pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-190b |
Genomic Coordinates | chr1: 154193665 - 154193743 |
Description | Homo sapiens miR-190b stem-loop |
Comment | None |
RNA Secondary Structure | ![]() |
Associated Diseases | ![]() |
Mature miRNA Information | |
---|---|
Mature miRNA | hsa-miR-190b |
Sequence | 11| UGAUAUGUUUGAUAUUGGGUU |31 |
Evidence | Not_experimental |
Experiments | |
Putative Targets |
miRNA Expression profile | |
---|---|
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | DUSP10 | ||||||||||||||||||||
Synonyms | MKP-5, MKP5 | ||||||||||||||||||||
Description | dual specificity phosphatase 10 | ||||||||||||||||||||
Transcript | NM_007207 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on DUSP10 | |||||||||||||||||||||
3'UTR of DUSP10 (miRNA target sites are highlighted) |
>DUSP10|NM_007207|3'UTR 1 CAATGGTCTGGATGGAAAGGATTGCTGCTCTCCATTAGGAGACAATGAGGAAGGAGGATGGATTCTGGTTTTTTTTCTTT 81 CTTTTTTTTTTTGTAGTTGGGAGTAAGTTTGTGAATGGAAACAAACTTGTTTAAACACTTTATTTTTAACAAGTGTAAGA 161 AGACTATAACTTTTGATGCCATTGAGATTCACCTCCCACAAACTGACAAATTAAGGAGGTTAAAGAAGTAATTTTTTTAA 241 GCCAACAATAAAAATATAATACAACTTGTTTCTCCCCCTTTTCCTTTTAAGCTATTTGTAGAGTTTATGACTAAATAGTC 321 TGTGCAGGTTCATAGACCGAAGATACTACACACTTTAAACCAATTAAAAAGAACCAAAAGTAAATAGAAAAGACATTGAA 401 TCACCAAGGCCTGGGATCAACCTGGGCTGTCCACACAGAAAACAAAAACCCAACCAAACCAAGCCCTGTTGTGCTCACTG 481 GTGCAAAGAGAAGATCAGGGCAGCTTAAGTGGTCTAAGAATCCTTCAGGCATTCTTTAAGGAGAAAAAGGATACCTTTGA 561 TTTTGTGTGTTTCATGCTCTGGATTTTTTTTTTTTTTCCTTCTCTGGGTTTAAGAGATTTTTTTTGAAATAGTGAGGAAC 641 TGACCATTATATGCCTTCACTGGCTTCTTGTGCAATAATATGATGTTTTAAGTGTGCAAACAAGTTAGAGCTGGCAGCTG 721 AATGATAGACAAATAGTGCAAATTTGCCAGCTTGGAGATAGAAAGGAATTCAACAATATATCAAATACTTTCCTTCCCAC 801 CTTTTTCCTTTTTTTTTTTTTTTTCTGATTTGATTCTGGTTACAGTGCCATAAACCTTGTTACATATGTATATCAGAATG 881 TAAGAAAAAAAAATTTATTTAAAAATATTTTTCGCAAAAAAAAAAAAAATCTTGGTGTGTTTCTGTTGATTGTGTAAAAA 961 TTTATTTTCATTATATAAATGAAACTGGTTTA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | HEK293S |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
HITS-CLIP data was present in GSM1084065. RNA binding protein: AGO2. Condition:CLIP_emetine_AbnovaAb
... - Karginov FV; Hannon GJ, 2013, Genes & development. |
Article |
- Karginov FV; Hannon GJ - Genes & development, 2013
When adapting to environmental stress, cells attenuate and reprogram their translational output. In part, these altered translation profiles are established through changes in the interactions between RNA-binding proteins and mRNAs. The Argonaute 2 (Ago2)/microRNA (miRNA) machinery has been shown to participate in stress-induced translational up-regulation of a particular mRNA, CAT-1; however, a detailed, transcriptome-wide understanding of the involvement of Ago2 in the process has been lacking. Here, we profiled the overall changes in Ago2-mRNA interactions upon arsenite stress by cross-linking immunoprecipitation (CLIP) followed by high-throughput sequencing (CLIP-seq). Ago2 displayed a significant remodeling of its transcript occupancy, with the majority of 3' untranslated region (UTR) and coding sequence (CDS) sites exhibiting stronger interaction. Interestingly, target sites that were destined for release from Ago2 upon stress were depleted in miRNA complementarity signatures, suggesting an alternative mode of interaction. To compare the changes in Ago2-binding patterns across transcripts with changes in their translational states, we measured mRNA profiles on ribosome/polysome gradients by RNA sequencing (RNA-seq). Increased Ago2 occupancy correlated with stronger repression of translation for those mRNAs, as evidenced by a shift toward lighter gradient fractions upon stress, while release of Ago2 was associated with the limited number of transcripts that remained translated. Taken together, these data point to a role for Ago2 and the mammalian miRNAs in mediating the translational component of the stress response.
LinkOut: [PMID: 23824327]
|
CLIP-seq Support 1 for dataset GSM1084065 | |
---|---|
Method / RBP | HITS-CLIP / AGO2 |
Cell line / Condition | HEK293S / CLIP_emetine_AbnovaAb |
Location of target site | ENST00000366899.3 | 3UTR | AUAGGGAAAGAGAGAUGAGGAAGGGAAC |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23824327 / GSE44404 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
60 hsa-miR-190b Target Genes:
Functional analysis:
ID![]() |
Target | Description | Validation methods |
![]() |
![]() |
|||||||
Strong evidence | Less strong evidence | |||||||||||
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
|||||
MIRT054581 | IGF1 | insulin like growth factor 1 | ![]() |
![]() |
![]() |
![]() |
4 | 1 | ||||
MIRT066966 | ATXN7L3B | ataxin 7 like 3B | ![]() |
![]() |
2 | 2 | ||||||
MIRT192449 | SPRED1 | sprouty related EVH1 domain containing 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT250414 | TNRC6A | trinucleotide repeat containing 6A | ![]() |
![]() |
2 | 2 | ||||||
MIRT306294 | KLHL24 | kelch like family member 24 | ![]() |
![]() |
2 | 2 | ||||||
MIRT355845 | SGMS2 | sphingomyelin synthase 2 | ![]() |
![]() |
2 | 4 | ||||||
MIRT437770 | MTMR6 | myotubularin related protein 6 | ![]() |
1 | 1 | |||||||
MIRT437771 | MTMR6 | myotubularin related protein 6 | ![]() |
1 | 1 | |||||||
MIRT437772 | Mtmr6 | myotubularin related protein 6 | ![]() |
1 | 1 | |||||||
MIRT444672 | CDKL2 | cyclin dependent kinase like 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT446389 | PCDHB11 | protocadherin beta 11 | ![]() |
![]() |
2 | 2 | ||||||
MIRT446634 | SDC3 | syndecan 3 | ![]() |
![]() |
2 | 2 | ||||||
MIRT449410 | TRIM5 | tripartite motif containing 5 | ![]() |
![]() |
2 | 2 | ||||||
MIRT449560 | GPC5 | glypican 5 | ![]() |
![]() |
2 | 2 | ||||||
MIRT469928 | PTPRJ | protein tyrosine phosphatase, receptor type J | ![]() |
![]() |
2 | 6 | ||||||
MIRT473736 | MAP3K9 | mitogen-activated protein kinase kinase kinase 9 | ![]() |
![]() |
2 | 2 | ||||||
MIRT474210 | LDHA | lactate dehydrogenase A | ![]() |
![]() |
2 | 2 | ||||||
MIRT474583 | KLF6 | Kruppel like factor 6 | ![]() |
![]() |
2 | 2 | ||||||
MIRT476732 | FOXN2 | forkhead box N2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT478455 | DAB2 | DAB2, clathrin adaptor protein | ![]() |
![]() |
2 | 2 | ||||||
MIRT495327 | ADAMTS8 | ADAM metallopeptidase with thrombospondin type 1 motif 8 | ![]() |
![]() |
2 | 4 | ||||||
MIRT498615 | MTRNR2L10 | MT-RNR2-like 10 | ![]() |
![]() |
2 | 12 | ||||||
MIRT501734 | OVOL1 | ovo like transcriptional repressor 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT501849 | MTRNR2L8 | MT-RNR2-like 8 | ![]() |
![]() |
2 | 14 | ||||||
MIRT504678 | CYGB | cytoglobin | ![]() |
![]() |
2 | 4 | ||||||
MIRT506517 | MSANTD4 | Myb/SANT DNA binding domain containing 4 with coiled-coils | ![]() |
![]() |
2 | 6 | ||||||
MIRT507984 | BCL2L13 | BCL2 like 13 | ![]() |
![]() |
2 | 4 | ||||||
MIRT508444 | ZNF608 | zinc finger protein 608 | ![]() |
![]() |
2 | 4 | ||||||
MIRT511366 | IL6ST | interleukin 6 signal transducer | ![]() |
![]() |
2 | 4 | ||||||
MIRT520515 | TRA2B | transformer 2 beta homolog | ![]() |
![]() |
2 | 2 | ||||||
MIRT524571 | CALML4 | calmodulin like 4 | ![]() |
![]() |
2 | 4 | ||||||
MIRT531896 | INVS | inversin | ![]() |
![]() |
2 | 4 | ||||||
MIRT533916 | TATDN2 | TatD DNase domain containing 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT537503 | FAM13B | family with sequence similarity 13 member B | ![]() |
![]() |
2 | 2 | ||||||
MIRT541689 | CCDC160 | coiled-coil domain containing 160 | ![]() |
![]() |
2 | 8 | ||||||
MIRT544419 | ZNF460 | zinc finger protein 460 | ![]() |
![]() |
2 | 4 | ||||||
MIRT544615 | CSDE1 | cold shock domain containing E1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT545076 | IL7R | interleukin 7 receptor | ![]() |
![]() |
2 | 2 | ||||||
MIRT545849 | ZNF264 | zinc finger protein 264 | ![]() |
![]() |
2 | 4 | ||||||
MIRT547436 | MED4 | mediator complex subunit 4 | ![]() |
![]() |
2 | 2 | ||||||
MIRT550157 | ZNF223 | zinc finger protein 223 | ![]() |
![]() |
2 | 4 | ||||||
MIRT553948 | STAMBP | STAM binding protein | ![]() |
![]() |
2 | 2 | ||||||
MIRT554395 | SERP1 | stress associated endoplasmic reticulum protein 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT555667 | PGAM4 | phosphoglycerate mutase family member 4 | ![]() |
![]() |
2 | 4 | ||||||
MIRT564193 | PM20D2 | peptidase M20 domain containing 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT566792 | MKL2 | MKL1/myocardin like 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT566843 | LRRC58 | leucine rich repeat containing 58 | ![]() |
![]() |
2 | 2 | ||||||
MIRT572516 | KIAA0232 | KIAA0232 | ![]() |
![]() |
2 | 2 | ||||||
MIRT607428 | NOTCH2NL | notch 2 N-terminal like | ![]() |
![]() |
2 | 10 | ||||||
MIRT627779 | RAB30 | RAB30, member RAS oncogene family | ![]() |
![]() |
2 | 2 | ||||||
MIRT635159 | ENO4 | enolase family member 4 | ![]() |
![]() |
2 | 2 | ||||||
MIRT642159 | ADCYAP1R1 | ADCYAP receptor type I | ![]() |
![]() |
![]() |
3 | 2 | |||||
MIRT646205 | DUSP10 | dual specificity phosphatase 10 | ![]() |
![]() |
2 | 2 | ||||||
MIRT657007 | KCNMB4 | potassium calcium-activated channel subfamily M regulatory beta subunit 4 | ![]() |
![]() |
2 | 2 | ||||||
MIRT665817 | TMEM161B | transmembrane protein 161B | ![]() |
![]() |
2 | 2 | ||||||
MIRT667488 | MAP3K2 | mitogen-activated protein kinase kinase kinase 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT707098 | ZNF850 | zinc finger protein 850 | ![]() |
![]() |
2 | 2 | ||||||
MIRT708719 | PTPLAD2 | 3-hydroxyacyl-CoA dehydratase 4 | ![]() |
1 | 1 | |||||||
MIRT735521 | HUS1 | HUS1 checkpoint clamp component | ![]() |
![]() |
![]() |
3 | 0 | |||||
MIRT736644 | AGPAT3 | 1-acylglycerol-3-phosphate O-acyltransferase 3 | ![]() |
![]() |
2 | 0 |
miRNA-Drug Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|